Home＞REGULATORY
Harvoni, Sovaldi under Review for Risks of Hypertension, Cerebrovascular Disorder(Jun.13.2016)
The Pharmaceuticals and Medical Devices Agency (PMDA) said on June 10 that it is reviewing the risks of hypertension and cerebrovascular disorder for hepatitis C drugs Harvoni (ledipasvir + sofosbuvir) and Sovaldi (sofosbuvir), a move that is likely to result ...
(LOG IN FOR FULL STORY)
-
- MHLW Panel Approves Increase in Raw Plasma Allocation to Nihon Pharmaceutical to 350,000 Liters Sep.22
-
Kaketsuken in Talks with “Several Entities” over Possible Biz Transfer: New Chief
Sep.21
-
MHLW to Consider Use of New Comprehensive Test System to Promote Practical Use of Genomic Medicine for Cancer: Official
Sep.21
- MHLW Issues Notification on Drug Criteria for Optimal Use Guidelines Sep.20
- Japan Drug Spending Logs 1st Fall in FY2016 Sep.19
- Teva’s Parkinson’s Med Delivers Positive Data in Japan PIII: Takeda(Sep.22)
- Medipal to Become JCR’s Top Shareholder, Poised to Form JV in US(Sep.22)
- Yasuhiro Onaka Tapped for Takeda’s Japan Sales Head(Sep.22)
- CSL Ramping Up Investment for New Product Development, 11% R&D-to-Sales Ratio “Appropriate”: CEO(Sep.22)
- MHLW Panel Approves Increase in Raw Plasma Allocation to Nihon Pharmaceutical to 350,000 Liters(Sep.22)
